Theranexus begins enrolment for Phase II trial of THN102 to treat narcolepsy-caused sleepiness

Theranexus has enrolled the first patient for its Phase II clinical study of THN102 to treat excessive daytime sleepiness associated with narcolepsy in adult patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news